Three-Year Clinical Outcomes With the Cilotax Dual Drug-Eluting Stent vs Everolimus-Eluting Stents in Patients With Acute Myocardial Infarction
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Yu, HyeYon | - |
dc.contributor.author | Ahn, Jihun | - |
dc.contributor.author | Choi, Byoung Geol | - |
dc.contributor.author | Park, Soohyung | - |
dc.contributor.author | Kang, Dong Oh | - |
dc.contributor.author | Choi, Cheol Ung | - |
dc.contributor.author | Rha, Seung-Woon | - |
dc.contributor.author | Jeong, Myung Ho | - |
dc.date.accessioned | 2024-06-11T09:32:01Z | - |
dc.date.available | 2024-06-11T09:32:01Z | - |
dc.date.issued | 2024-01 | - |
dc.identifier.issn | 0730-2347 | - |
dc.identifier.issn | 1526-6702 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/26297 | - |
dc.description.abstract | Background: This study compared the safety and effectiveness of paclitaxel/cilostazol-eluting Cilotax stents with those of everolimus-eluting stents in patients with acute myocardial infarction. Real-world data from the Korea Acute Myocardial Infarction Registry were examined. Methods: A total of 5,472 patients with acute myocardial infarction underwent percutaneous coronary intervention with Cilotax stents (n = 212) or everolimus-eluting stents (n = 5,260). The primary end point was the 3-year rate of target lesion failure. The other end points were major adverse cardiovascular events (a composite of cardiac death, target vessel myocardial infarction, and ischemia-driven target lesion revascularization), target vessel revascularization, and stent thrombosis. A propensity score matching analysis was performed to adjust for potential confounders by using a logistic regression model; propensity score matching generated 2 well-balanced groups (Cilotax group, n = 180; everolimus-eluting stents group, n = 170; N = 350). After propensity score matching, baseline clinical characteristics were similar between the groups. Results: After percutaneous coronary intervention, compared with the everolimus-eluting stents group, the Cilotax group more often had major adverse cardiovascular events (24.1% vs 18.5%; P =.042), myocardial infarction (8.0% vs 3.2%; P <.001), target lesion revascularization (8.0% vs 2.6%; P <.001), target vessel revascularization (11.3% vs 4.5%; P <.001), and stent thrombosis (4.7% vs 0.5%; P <.001) before matching. Even after matching, the Cilotax group had more frequent target lesion revascularization (9.4% vs 2.9%; P =.22) and stent thrombosis (5.6% vs 1.2%; P =.34). Conclusion: In patients with acute myocardial infarction who underwent percutaneous coronary intervention, use of the Cilotax stent was associated with higher rates of target lesion revascularization, target vessel revascularization, and stent thrombosis than were everolimus-eluting stents. Use of the Cilotax dual drugeluting stent should be avoided in the treatment of myocardial infarction. | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | TEXAS HEART INST | - |
dc.title | Three-Year Clinical Outcomes With the Cilotax Dual Drug-Eluting Stent vs Everolimus-Eluting Stents in Patients With Acute Myocardial Infarction | - |
dc.type | Article | - |
dc.publisher.location | 미국 | - |
dc.identifier.doi | 10.14503/THIJ-23-8271 | - |
dc.identifier.scopusid | 2-s2.0-85191924393 | - |
dc.identifier.wosid | 001223516900006 | - |
dc.identifier.bibliographicCitation | TEXAS HEART INSTITUTE JOURNAL, v.51, no.1 | - |
dc.citation.title | TEXAS HEART INSTITUTE JOURNAL | - |
dc.citation.volume | 51 | - |
dc.citation.number | 1 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Cardiovascular System & Cardiology | - |
dc.relation.journalWebOfScienceCategory | Cardiac & Cardiovascular Systems | - |
dc.subject.keywordPlus | THROMBOSIS | - |
dc.subject.keywordPlus | 1ST-GENERATION | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordPlus | GUIDELINES | - |
dc.subject.keywordPlus | MANAGEMENT | - |
dc.subject.keywordPlus | CILOSTAZOL | - |
dc.subject.keywordPlus | REGISTRY | - |
dc.subject.keywordAuthor | Myocardial infarction | - |
dc.subject.keywordAuthor | drug-eluting stents | - |
dc.subject.keywordAuthor | percutaneous coronary intervention | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.